{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:54Z","timestamp":1791571794590,"version":"4.3.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"abstract":"<jats:title>\n                <jats:bold>Abstract<\/jats:bold>\n              <\/jats:title><jats:p>Vav1 is physiologically active as a GDP\/GTP nucleotide exchange factor (GEF) in the hematopoietic system. Overexpression of Vav1 in multiple tumor types is known to enhance oncogenicity, yet whether or not Vav1 is a bona fide oncogene is still a matter of debate. Although mutations in Vav1 were recently identified in human cancers of various origins, the functional activities of these mutants are not known. We tested the transforming potential of three mutations identified in human lung adenocarcinoma: E59K, D517E, and L801P. Results from several assays indicative of transforming activities such as rate of proliferation, growth in agar, and generation of tumors in NOD\/SCID mice clearly indicated that E59K and D517E are highly transforming but L801P at the SH3 domain is not. The acquired oncogenic activity of these mutants can be attributed to their enhanced activity as GEFs for Rho\/Rac GTPases. Deciphering of the mechanisms leading to overactivity of the tested mutants revealed that the E59K mutation facilitates cleavage of a truncated protein that is uncontrollably active as a GEF, while D517E generates a highly stable overexpressed protein that is also more active as a GEF than wild-type Vav1. These findings support the classification of Vav1 as a bona fide oncogene in human cancer.<\/jats:p>","DOI":"10.1038\/s41389-018-0091-1","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T09:12:19Z","timestamp":1538989939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes"],"prefix":"10.1038","volume":"7","author":[{"given":"Batel","family":"Shalom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marganit","family":"Farago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Pikarsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6878-2139","authenticated-orcid":false,"given":"Shulamit","family":"Katzav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"91_CR1","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1002\/j.1460-2075.1989.tb08354.x","volume":"8","author":"S Katzav","year":"1989","unstructured":"Katzav, S., Martin-Zanca, D. & Barbacid, M. vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J. 8, 2283\u20132290 (1989).","journal-title":"EMBO J."},{"key":"91_CR2","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1128\/MCB.11.4.1912","volume":"11","author":"S Katzav","year":"1991","unstructured":"Katzav, S., Cleveland, J. L., Heslop, H. E. & Pulido, D. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol. Cell Biol. 11, 1912\u20131920 (1991).","journal-title":"Mol. Cell Biol."},{"key":"91_CR3","first-page":"95","volume":"2","author":"J Coppola","year":"1991","unstructured":"Coppola, J., Bryant, S., Koda, T., Conway, D. & Barbacid, M. Mechanism of activation of the vav protooncogene. Cell Growth Differ. 2, 95\u2013105 (1991).","journal-title":"Cell Growth Differ."},{"key":"91_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.coi.2005.04.003","volume":"17","author":"VL Tybulewicz","year":"2005","unstructured":"Tybulewicz, V. L. Vav-family proteins in T-cell signalling. Curr. Opin. Immunol. 17, 267\u2013274 (2005).","journal-title":"Curr. Opin. Immunol."},{"key":"91_CR5","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1128\/MCB.20.5.1461-1477.2000","volume":"20","author":"XR Bustelo","year":"2000","unstructured":"Bustelo, X. R. Regulatory and signaling properties of the Vav family. Mol. Cell Biol. 20, 1461\u20131477 (2000).","journal-title":"Mol. Cell Biol."},{"key":"91_CR6","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood-2003-08-2834","volume":"103","author":"S Katzav","year":"2004","unstructured":"Katzav, S. Vav1: an oncogene that regulates specific transcriptional activation of T cells. Blood 103, 2443\u20132451 (2004).","journal-title":"Blood"},{"key":"91_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.biocel.2008.11.006","volume":"41","author":"S Katzav","year":"2009","unstructured":"Katzav, S. Vav1: a hematopoietic signal transduction molecule involved in human malignancies. Int. J. Biochem. Cell Biol. 41, 1245\u20131248 (2009).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"91_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.molimm.2010.12.007","volume":"48","author":"T Kurosaki","year":"2011","unstructured":"Kurosaki, T. Regulation of BCR signaling. Mol. Immunol. 48, 1287\u20131291 (2011).","journal-title":"Mol. Immunol."},{"key":"91_CR9","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1038\/onc.2013.362","volume":"33","author":"DR Cook","year":"2014","unstructured":"Cook, D. R., Rossman, K. L. & Der, C. J. Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene 33, 4021\u20134035 (2014).","journal-title":"Oncogene"},{"key":"91_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/385169a0","volume":"385","author":"P Crespo","year":"1997","unstructured":"Crespo, P., Schuebel, K. E., Ostrom, A. A., Gutkind, J. S. & Bustelo, X. R. Phosphotyrosine-dependent activation of Rac-1 GDP\/GTP exchange by the vav proto-oncogene product. Nature 385, 169\u2013172 (1997).","journal-title":"Nature"},{"key":"91_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/path.1314","volume":"199","author":"I Hornstein","year":"2003","unstructured":"Hornstein, I. et al. The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas. J. Pathol. 199, 526\u2013533 (2003).","journal-title":"J. Pathol."},{"key":"91_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/path.2579","volume":"219","author":"G Lazer","year":"2009","unstructured":"Lazer, G., Idelchuk, Y., Schapira, V., Pikarsky, E. & Katzav, S. The haematopoietic specific signal transducer Vav1 is aberrantly expressed in lung cancer and plays a role in tumourigenesis. J. Pathol. 219, 25\u201334 (2009).","journal-title":"J. Pathol."},{"key":"91_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054321","volume":"8","author":"S Sebban","year":"2013","unstructured":"Sebban, S. et al. Vav1 fine tunes p53 control of apoptosis versus proliferation in breast cancer. PLoS ONE 8, e54321 (2013).","journal-title":"PLoS ONE"},{"key":"91_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ccr.2004.11.024","volume":"7","author":"ME Fernandez-Zapico","year":"2005","unstructured":"Fernandez-Zapico, M. E. et al. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 7, 39\u201349 (2005).","journal-title":"Cancer Cell"},{"key":"91_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.trsl.2013.06.005","volume":"162","author":"S Wakahashi","year":"2013","unstructured":"Wakahashi, S. et al. VAV1 represses E-cadherin expression through the transactivation of Snail and Slug: a potential mechanism for aberrant epithelial to mesenchymal transition in human epithelial ovarian cancer. Transl. Res. 162, 181\u2013190 (2013).","journal-title":"Transl. Res."},{"key":"91_CR16","first-page":"97","volume":"37","author":"P Kniazev Iu","year":"2003","unstructured":"Kniazev Iu, P. et al. [Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma]. Mol. Biol. (Mosk.) 37, 97\u2013111 (2003).","journal-title":"Mol. Biol. (Mosk.)"},{"key":"91_CR17","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbrc.2017.03.091","volume":"486","author":"X Zhu","year":"2017","unstructured":"Zhu, X. et al. Vav1 expression is increased in esophageal squamous cell carcinoma and indicates poor prognosis. Biochem. Biophys. Res. Commun. 486, 571\u2013576 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"91_CR18","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1038\/onc.2014.405","volume":"34","author":"JC Lindsey","year":"2014","unstructured":"Lindsey, J. C. et al. Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance. Oncogene 34, 4746\u20134757 (2014).","journal-title":"Oncogene"},{"key":"91_CR19","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1038\/onc.2016.378","volume":"36","author":"PH Huang","year":"2017","unstructured":"Huang, P. H. et al. TGFbeta promotes mesenchymal phenotype of pancreatic cancer cells, in part, through epigenetic activation of VAV1. Oncogene 36, 2202\u20132214 (2017).","journal-title":"Oncogene"},{"key":"91_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.canlet.2007.04.015","volume":"255","author":"S Katzav","year":"2007","unstructured":"Katzav, S. Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies. Cancer Lett. 255, 241\u2013254 (2007).","journal-title":"Cancer Lett."},{"key":"91_CR21","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1128\/MCB.20.5.1678-1691.2000","volume":"20","author":"M Lopez-Lago","year":"2000","unstructured":"Lopez-Lago, M., Lee, H., Cruz, C., Movilla, N. & Bustelo, X. R. Tyrosine phosphorylation mediates both activation and downmodulation of the biological activity of Vav. Mol. Cell Biol. 20, 1678\u20131691 (2000).","journal-title":"Mol. Cell Biol."},{"key":"91_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0092-8674(00)00085-4","volume":"102","author":"B Aghazadeh","year":"2000","unstructured":"Aghazadeh, B., Lowry, W. E., Huang, X. Y. & Rosen, M. K. Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell 102, 625\u2013633 (2000).","journal-title":"Cell"},{"key":"91_CR23","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.18632\/oncotarget.2629","volume":"6","author":"L Razanadrakoto","year":"2015","unstructured":"Razanadrakoto, L. et al. Mutation of Vav1 adaptor region reveals a new oncogenic activation. Oncotarget 6, 2524\u20132537 (2015).","journal-title":"Oncotarget"},{"key":"91_CR24","first-page":"1757","volume":"8","author":"S Katzav","year":"1993","unstructured":"Katzav, S. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav. Oncogene 8, 1757\u20131763 (1993).","journal-title":"Oncogene"},{"key":"91_CR25","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/sj.onc.1202074","volume":"17","author":"M Groysman","year":"1998","unstructured":"Groysman, M., Nagano, M., Shaanan, B. & Katzav, S. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation. Oncogene 17, 1597\u20131606 (1998).","journal-title":"Oncogene"},{"key":"91_CR26","doi-asserted-by":"publisher","first-page":"23073","DOI":"10.1074\/jbc.M109.094508","volume":"285","author":"G Lazer","year":"2010","unstructured":"Lazer, G. et al. Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity. J. Biol. Chem. 285, 23073\u201323083 (2010).","journal-title":"J. Biol. Chem."},{"key":"91_CR27","doi-asserted-by":"publisher","first-page":"45377","DOI":"10.1074\/jbc.M208039200","volume":"277","author":"JL Zugaza","year":"2002","unstructured":"Zugaza, J. L. et al. Structural determinants for the biological activity of Vav proteins. J. Biol. Chem. 277, 45377\u201345392 (2002).","journal-title":"J. Biol. Chem."},{"key":"91_CR28","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka, K. et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat. Genet. 47, 1304\u20131315 (2015).","journal-title":"Nat. Genet."},{"key":"91_CR29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1073\/pnas.1608839114","volume":"114","author":"F Abate","year":"2017","unstructured":"Abate, F. et al. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proc. Natl Acad. Sci. USA 114, 764\u2013769 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"91_CR30","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","volume":"128","author":"RL Boddicker","year":"2016","unstructured":"Boddicker, R. L. et al. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood 128, 1234\u20131245 (2016).","journal-title":"Blood"},{"key":"91_CR31","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois, D. et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128, 1490\u20131502 (2016).","journal-title":"Blood"},{"key":"91_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.3564","volume":"48","author":"JD Campbell","year":"2016","unstructured":"Campbell, J. D. et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 48, 607\u2013616 (2016).","journal-title":"Nat. Genet."},{"key":"91_CR33","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1073\/pnas.96.6.3035","volume":"96","author":"PS Costello","year":"1999","unstructured":"Costello, P. S. et al. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kappaB pathways. Proc. Natl Acad. Sci. USA 96, 3035\u20133040 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"91_CR34","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/embor.2008.80","volume":"9","author":"J Rapley","year":"2008","unstructured":"Rapley, J., Tybulewicz, V. L. & Rittinger, K. Crucial structural role for the PH and C1 domains of the Vav1 exchange factor. EMBO Rep. 9, 655\u2013661 (2008).","journal-title":"EMBO Rep."},{"key":"91_CR35","doi-asserted-by":"crossref","first-page":"20225","DOI":"10.1016\/S0021-9258(17)31979-8","volume":"269","author":"O Hobert","year":"1994","unstructured":"Hobert, O., Jallal, B., Schlessinger, J. & Ullrich, A. Novel signaling pathway suggested by SH3 domain-mediated p95vav\/heterogeneous ribonucleoprotein K interaction. J. Biol. Chem. 269, 20225\u201320228 (1994).","journal-title":"J. Biol. Chem."},{"key":"91_CR36","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.cellsig.2007.07.022","volume":"19","author":"G Lazer","year":"2007","unstructured":"Lazer, G., Pe\u2019er, L., Schapira, V., Richard, S. & Katzav, S. The association of Sam68 with Vav1 contributes to tumorigenesis. Cell. Signal. 19, 2479\u20132486 (2007).","journal-title":"Cell. Signal."},{"key":"91_CR37","first-page":"1577","volume":"12","author":"O Hobert","year":"1996","unstructured":"Hobert, O., Schilling, J. W., Beckerle, M. C., Ullrich, A. & Jallal, B. SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin. Oncogene 12, 1577\u20131581 (1996).","journal-title":"Oncogene"},{"key":"91_CR38","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/nri840","volume":"2","author":"M Turner","year":"2002","unstructured":"Turner, M. & Billadeau, D. D. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat. Rev. Immunol. 2, 476\u2013486 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"91_CR39","first-page":"455","volume":"13","author":"P Crespo","year":"1996","unstructured":"Crespo, P. et al. Rac-1 dependent stimulation of the JNK\/SAPK signaling pathway by Vav. Oncogene 13, 455\u2013460 (1996).","journal-title":"Oncogene"},{"key":"91_CR40","doi-asserted-by":"crossref","first-page":"28731","DOI":"10.18632\/oncotarget.5086","volume":"6","author":"S Katzav","year":"2015","unstructured":"Katzav, S. Vav1: A Dr. Jekyll and Mr. Hyde protein - good for the hematopoietic system, bad for cancer. Oncotarget 6, 28731\u2013289742 (2015).","journal-title":"Oncotarget"},{"key":"91_CR41","doi-asserted-by":"crossref","first-page":"15966","DOI":"10.18632\/oncotarget.3862","volume":"6","author":"CY Liu","year":"2015","unstructured":"Liu, C. Y., Lin, H. H., Tang, M. J. & Wang, Y. K. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget 6, 15966\u201315983 (2015).","journal-title":"Oncotarget"},{"key":"91_CR42","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420\u20131428 (2009).","journal-title":"J. Clin. Invest."},{"key":"91_CR43","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/labinvest.3700683","volume":"87","author":"P Damonte","year":"2007","unstructured":"Damonte, P., Gregg, J. P., Borowsky, A. D. & Keister, B. A. & CardiffR. D. EMT tumorigenesis in the mouse mammary gland. Lab. Invest. 87, 1218\u20131226 (2007).","journal-title":"Lab. Invest."},{"key":"91_CR44","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/0008-5472.CAN-07-2017","volume":"68","author":"D Sarrio","year":"2008","unstructured":"Sarrio, D. et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68, 989\u2013997 (2008).","journal-title":"Cancer Res."},{"key":"91_CR45","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1172\/JCI36183","volume":"119","author":"M Zeisberg","year":"2009","unstructured":"Zeisberg, M. & Neilson, E. G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 119, 1429\u20131437 (2009).","journal-title":"J. Clin. Invest."},{"key":"91_CR46","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/297474a0","volume":"297","author":"LF Parada","year":"1982","unstructured":"Parada, L. F., Tabin, C. J., Shih, C. & Weinberg, R. A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297, 474\u2013478 (1982).","journal-title":"Nature"},{"key":"91_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1128\/MCB.5.1.259","volume":"5","author":"UP Thorgeirsson","year":"1985","unstructured":"Thorgeirsson, U. P. et al. NIH\/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastatic phenotype in nude mice. Mol. Cell Biol. 5, 259\u2013262 (1985).","journal-title":"Mol. Cell Biol."},{"key":"91_CR48","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/304596a0","volume":"304","author":"H Land","year":"1983","unstructured":"Land, H., Parada, L. F. & Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596\u2013602 (1983).","journal-title":"Nature"},{"key":"91_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1083\/jcb.17.2.299","volume":"17","author":"GJ Todaro","year":"1963","unstructured":"Todaro, G. J. & Green, H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17, 299\u2013313 (1963).","journal-title":"J. Cell Biol."},{"key":"91_CR50","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/304648a0","volume":"304","author":"RF Newbold","year":"1983","unstructured":"Newbold, R. F. & Overell, R. W. Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304, 648\u2013651 (1983).","journal-title":"Nature"},{"key":"91_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018542","volume":"6","author":"J Chiang","year":"2011","unstructured":"Chiang, J. & Hodes, R. J. Cbl enforces Vav1 dependence and a restricted pathway of T cell development. PLoS ONE 6, e18542 (2011).","journal-title":"PLoS ONE"},{"key":"91_CR52","doi-asserted-by":"publisher","first-page":"38495","DOI":"10.1074\/jbc.M305656200","volume":"278","author":"Y Miura-Shimura","year":"2003","unstructured":"Miura-Shimura, Y. et al. Cbl-mediated ubiquitinylation and negative regulation of Vav. J. Biol. Chem. 278, 38495\u201338504 (2003).","journal-title":"J. Biol. Chem."},{"key":"91_CR53","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/sj.onc.1203406","volume":"19","author":"TG Hofmann","year":"2000","unstructured":"Hofmann, T. G., Hehner, S. P., Droge, W. & Schmitz, M. L. Caspase-dependent cleavage and inactivation of the Vav1 proto-oncogene product during apoptosis prevents IL-2 transcription. Oncogene 19, 1153\u20131163 (2000).","journal-title":"Oncogene"},{"key":"91_CR54","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cell.2015.03.001","volume":"161","author":"Y Kravtsova-Ivantsiv","year":"2015","unstructured":"Kravtsova-Ivantsiv, Y. et al. KPC1-mediated ubiquitination and proteasomal processing of NF-kappaB1p105 to p50 restricts tumor growth. Cell 161, 333\u2013347 (2015).","journal-title":"Cell"},{"key":"91_CR55","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.molcel.2004.10.017","volume":"16","author":"JM Baugh","year":"2004","unstructured":"Baugh, J. M. & Pilipenko, E. V. 20S proteasome differentially alters translation of different mRNAs via the cleavage of eIF4F and eIF3. Mol. Cell 16, 575\u2013586 (2004).","journal-title":"Mol. Cell"},{"issue":"5","key":"91_CR56","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1042\/BC20070121","volume":"100","author":"Constantina Constantinou","year":"2008","unstructured":"Constantinou, C., Elia, A. & Clemens, M. J. Activation of p53 stimulates proteasome-dependent truncation of eIF4E-binding protein 1 (4E-BP1). Biol. Cell 100, 279\u2013289 (2008).","journal-title":"Biology of the Cell"},{"key":"91_CR57","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1038\/sj.emboj.7600830","volume":"24","author":"AV Sorokin","year":"2005","unstructured":"Sorokin, A. V. et al. Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response. EMBO J. 24, 3602\u20133612 (2005).","journal-title":"EMBO J."},{"key":"91_CR58","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","volume":"32","author":"M Fujisawa","year":"2018","unstructured":"Fujisawa, M. et al. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia 32, 694\u2013702 (2018).","journal-title":"Leukemia"},{"key":"91_CR59","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1128\/MCB.15.8.4337","volume":"15","author":"J Wu","year":"1995","unstructured":"Wu, J., Katzav, S. & Weiss, A. A functional T-cell receptor signaling pathway is required for p95vav activity. Mol. Cell. Biol. 15, 4337\u20134346 (1995).","journal-title":"Mol. Cell. Biol."},{"key":"91_CR60","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cell.2009.12.033","volume":"140","author":"B Yu","year":"2010","unstructured":"Yu, B. et al. Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell 140, 246\u2013256 (2010).","journal-title":"Cell"},{"key":"91_CR61","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ccell.2017.10.004","volume":"32","author":"J Robles-Valero","year":"2017","unstructured":"Robles-Valero, J. et al. A paradoxical tumor-suppressor role for the Rac1 exchange factor Vav1 in T cell acute lymphoblastic leukemia. Cancer Cell 32, 608\u2013623 e609 (2017).","journal-title":"Cancer Cell"},{"key":"91_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-94-017-9211-0_5","volume":"85","author":"R Santoro","year":"2014","unstructured":"Santoro, R., Strano, S. & Blandino, G. Transcriptional regulation by mutant p53 and oncogenesis. Subcell. Biochem. 85, 91\u2013103 (2014).","journal-title":"Subcell. Biochem."},{"key":"91_CR63","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269\u2013271 (2004).","journal-title":"Science"},{"key":"91_CR64","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.1206923","volume":"333","author":"N Agrawal","year":"2011","unstructured":"Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154\u20131157 (2011).","journal-title":"Science"},{"issue":"2","key":"91_CR65","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ccr.2012.01.001","volume":"21","author":"Gen-Sheng Feng","year":"2012","unstructured":"Feng, G. S. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 21, 150\u2013154 (2012).","journal-title":"Cancer Cell"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-018-0091-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-018-0091-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-018-0091-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:14:02Z","timestamp":1671534842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-018-0091-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":65,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"alternative-id":["91"],"URL":"https:\/\/doi.org\/10.1038\/s41389-018-0091-1","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"19 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"80"}}